Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Trial Profile

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Phase of Trial: Phase III

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Dinutuximab beta (Primary) ; Aldesleukin; Busulfan; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Etoposide; Filgrastim; Isotretinoin; Melphalan; Vincristine
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Acronyms HR-NBL-1; HR-NBL-1.7; HR-NBL-1.8; HR-NBL1-1.5; SIOPEN
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Jan 2018 Planned number of patients changed from 2700 to 3300.
    • 07 Jun 2016 Results (subgroup analysis, n = 406) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top